메뉴 건너뛰기




Volumn 126, Issue 9 SUPPL.1, 2013, Pages

Intensifying insulin therapy: What options are available to patients with type 2 diabetes?

Author keywords

Basal insulin intensification; Basal plus insulin therapy; Basal bolus therapy hypoglycemia

Indexed keywords

AMYLIN RECEPTOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INCRETIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; PRAMLINTIDE; SULFONYLUREA DERIVATIVE;

EID: 84882253914     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2013.06.011     Document Type: Article
Times cited : (35)

References (44)
  • 1
    • 33646014162 scopus 로고    scopus 로고
    • Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
    • A.J. Garber, J. Wahlen, and T. Wahl Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) Diabetes Obes Metab 8 2006 58 66
    • (2006) Diabetes Obes Metab , vol.8 , pp. 58-66
    • Garber, A.J.1    Wahlen, J.2    Wahl, T.3
  • 2
    • 44049097336 scopus 로고    scopus 로고
    • Pramlintide,the synthetic analogue of amylin: Physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk
    • B.J. Hoogwerf, K.B. Doshi, and D. Diab Pramlintide, the synthetic analog of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk Vasc Health Risk Manag 4 2008 355 362 (Pubitemid 351711964)
    • (2008) Vascular Health and Risk Management , vol.4 , Issue.2 , pp. 355-362
    • Hoogwerf, B.J.1    Doshi, K.B.2    Diab, D.3
  • 3
    • 67649666737 scopus 로고    scopus 로고
    • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6)
    • J. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
    • (2009) Lancet , vol.374 , pp. 39-47
    • Buse, J.1    Rosenstock, J.2    Sesti, G.3
  • 4
    • 79551615182 scopus 로고    scopus 로고
    • Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial
    • J.B. Buse, R.M. Bergenstal, and L.C. Glass Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 154 2011 103 112
    • (2011) Ann Intern Med , vol.154 , pp. 103-112
    • Buse, J.B.1    Bergenstal, R.M.2    Glass, L.C.3
  • 5
    • 84862903186 scopus 로고    scopus 로고
    • Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets
    • J.H. DeVries, S.C. Bain, and H.W. Rodbard Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets Diabetes Care 35 2012 1446 1454
    • (2012) Diabetes Care , vol.35 , pp. 1446-1454
    • Devries, J.H.1    Bain, S.C.2    Rodbard, H.W.3
  • 6
    • 0242269000 scopus 로고    scopus 로고
    • The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    • DOI 10.2337/diacare.26.11.3080
    • M.C. Riddle, J. Rosenstock, J. Gerich Insulin Glargine 4002 Study Investigators The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086 (Pubitemid 37339502)
    • (2003) Diabetes Care , vol.26 , Issue.11 , pp. 3080-3086
    • Riddle, M.C.1    Rosenstock, J.2    Gerich, J.3
  • 7
    • 19944368427 scopus 로고    scopus 로고
    • Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine
    • DOI 10.2337/diacare.28.6.1282
    • M. Davies, F. Storms, and S. Shutler Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine Diabetes Care 28 2005 1282 1288 (Pubitemid 40756686)
    • (2005) Diabetes Care , vol.28 , Issue.6 , pp. 1282-1288
    • Davies, M.1    Storms, F.2    Shutler, S.3    Bianchi-Biscay, M.4    Gomis, R.5
  • 8
    • 33845236398 scopus 로고    scopus 로고
    • Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 Diabetes
    • DOI 10.1016/j.clinthera.2006.10.020, PII S0149291806002608
    • A. Philis-Tsimikas, G. Charpentier, P. Clauson, G.M. Ravn, V.L. Roberts, and B. Thorsteinsson Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 28 10 2006 1569 1581 (Pubitemid 44856694)
    • (2006) Clinical Therapeutics , vol.28 , Issue.10 , pp. 1569-1581
    • Philis-Tsimikas, A.1    Charpentier, G.2    Clauson, P.3    Ravn, G.M.4    Roberts, V.L.5    Thorsteinsson, B.6
  • 9
    • 65549131199 scopus 로고    scopus 로고
    • Patient-directed titration for achieving glycaemic goals using once-daily basal insulin analog: An assessment of two different fasting plasma glucose targets - The TITRATE study
    • TITRATE Study Group
    • L. Blonde, M. Merilainen, V. Karwe, P. Raskin TITRATE Study Group Patient-directed titration for achieving glycaemic goals using once-daily basal insulin analog: an assessment of two different fasting plasma glucose targets - the TITRATE study Diabetes Obes Metab 11 6 2009 623 631
    • (2009) Diabetes Obes Metab , vol.11 , Issue.6 , pp. 623-631
    • Blonde, L.1    Merilainen, M.2    Karwe, V.3    Raskin, P.4
  • 10
    • 84882271234 scopus 로고    scopus 로고
    • Initiating basal insulin therapy in type 2 diabetes: Practical steps to optimize glycemic control
    • A. Philis-Tsimikas Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control Am J Med 126 Suppl 2013 S21 S27
    • (2013) Am J Med , vol.126 , Issue.SUPPL.
    • Philis-Tsimikas, A.1
  • 11
    • 0042166232 scopus 로고    scopus 로고
    • 1c
    • DOI 10.2337/diacare.26.3.881
    • L. Monnier, H. Lapinski, and C. Colette Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) Diabetes Care 26 2003 881 885 (Pubitemid 36929359)
    • (2003) Diabetes Care , vol.26 , Issue.3 , pp. 881-885
    • Monnier, L.1    Lapinski, H.2    Colette, C.3
  • 12
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 55 2012 1577 1596
    • (2012) Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 13
    • 55449131463 scopus 로고    scopus 로고
    • Orals Plus Apidra and LANTUS (OPAL) Study Group. Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs
    • M.R. Lankisch, K.C. Ferlinz, J.L. Leahy, and W.A. Scherbaum Orals Plus Apidra and LANTUS (OPAL) Study Group. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs Diabetes Obes Metab 10 2008 1178 1185
    • (2008) Diabetes Obes Metab , vol.10 , pp. 1178-1185
    • Lankisch, M.R.1    Ferlinz, K.C.2    Leahy, J.L.3    Scherbaum, W.A.4
  • 14
    • 80054079094 scopus 로고    scopus 로고
    • A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: The step-wise randomized study
    • L. Meneghini, H. Mersebach, and S. Kumar A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study Endocr Pract 17 2011 727 736
    • (2011) Endocr Pract , vol.17 , pp. 727-736
    • Meneghini, L.1    Mersebach, H.2    Kumar, S.3
  • 15
    • 79959645873 scopus 로고    scopus 로고
    • A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure
    • M.B. Davidson, P. Raskin, and R.J. Tanenberg A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure Endocr Pract 17 2011 395 403
    • (2011) Endocr Pract , vol.17 , pp. 395-403
    • Davidson, M.B.1    Raskin, P.2    Tanenberg, R.J.3
  • 16
    • 49649123535 scopus 로고    scopus 로고
    • Adjust to target in type 2 diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
    • R.M. Bergenstal, M. Johnson, and M.A. Powers Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine Diabetes Care 31 2008 1305 1310
    • (2008) Diabetes Care , vol.31 , pp. 1305-1310
    • Bergenstal, R.M.1    Johnson, M.2    Powers, M.A.3
  • 17
    • 84872228197 scopus 로고    scopus 로고
    • Near normoglycaemic control under supplementary insulin therapy in type 2 diabetes with insulin aspart and insulin detemir - Is a fixed-dose regimen as effective as a flexible therapy regimen?
    • S412
    • K. Milek, E. Wizemann, and S. Martin Near normoglycaemic control under supplementary insulin therapy in type 2 diabetes with insulin aspart and insulin detemir - is a fixed-dose regimen as effective as a flexible therapy regimen? Diabetologia 50 Suppl 1 2007 S412
    • (2007) Diabetologia , vol.50 , Issue.SUPPL. 1
    • Milek, K.1    Wizemann, E.2    Martin, S.3
  • 18
    • 44849091537 scopus 로고    scopus 로고
    • When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study
    • DOI 10.1111/j.1742-1241.2008.01792.x
    • H.C. Jang, S. Guler, M. Shestakova PRESENT Study Group When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study Int J Clin Pract 62 2008 1013 1018 (Pubitemid 351793600)
    • (2008) International Journal of Clinical Practice , vol.62 , Issue.7 , pp. 1013-1018
    • Jang, H.C.1    Guler, S.2    Shestakova, M.3
  • 19
    • 58149177354 scopus 로고    scopus 로고
    • Comparison of insulin analog regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial
    • A. Liebl, R. Prager, and K. Binz Comparison of insulin analog regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial Diabetes Obes Metab 11 2009 45 52
    • (2009) Diabetes Obes Metab , vol.11 , pp. 45-52
    • Liebl, A.1    Prager, R.2    Binz, K.3
  • 20
    • 70350534273 scopus 로고    scopus 로고
    • Three-year efficacy of complex insulin regimens in type 2 diabetes
    • 4-T Study Group
    • R.R. Holman, A.J. Farmer, M.J. Davies 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 361 2009 1736 1747
    • (2009) N Engl J Med , vol.361 , pp. 1736-1747
    • Holman, R.R.1    Farmer, A.J.2    Davies, M.J.3
  • 21
    • 73349119110 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
    • T. Vilsbøll, J. Rosenstock, and Yki-Järvinen Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 12 2010 167 177
    • (2010) Diabetes Obes Metab , vol.12 , pp. 167-177
    • Vilsbøll, T.1    Rosenstock, J.2    Yki-Järvinen3
  • 22
    • 69549130787 scopus 로고    scopus 로고
    • Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes
    • M. Riddle, R. Pencek, and S. Charenkavanich Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes Diabetes Care 32 2009 1577 1582
    • (2009) Diabetes Care , vol.32 , pp. 1577-1582
    • Riddle, M.1    Pencek, R.2    Charenkavanich, S.3
  • 23
    • 78651338445 scopus 로고    scopus 로고
    • Standards of medical care in diabetes - 2011
    • American Diabetes Association Standards of medical care in diabetes - 2011 Diabetes Care 34 Suppl 1 2011 S11 S61
    • (2011) Diabetes Care , vol.34 , Issue.SUPPL. 1
  • 24
    • 74349094720 scopus 로고    scopus 로고
    • Perioperative management of diabetes: Translating evidence into practice
    • J. Meneghini Perioperative management of diabetes: translating evidence into practice Cleve Clin J Med 76 Suppl 4 2009 S53 S59
    • (2009) Cleve Clin J Med , vol.76 , Issue.SUPPL. 4
    • Meneghini, J.1
  • 25
    • 84882276623 scopus 로고    scopus 로고
    • AACE comprehensive diabetes management algorithm 2013
    • A.J. Garber, M.J. Abrahamson, and J.I. Barzilay AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
    • (2013) Endocr Pract , vol.19 , pp. 327-336
    • Garber, A.J.1    Abrahamson, M.J.2    Barzilay, J.I.3
  • 26
    • 77950813140 scopus 로고    scopus 로고
    • Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: Systematic review and economic evaluation
    • E. Cummins, P. Royle, and A. Snaith Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation Health Technol Assess 14 34, xi-xvi 2010 1 181
    • (2010) Health Technol Assess , vol.14 , Issue.34 , pp. 1-181
    • Cummins, E.1    Royle, P.2    Snaith, A.3
  • 28
    • 74949138626 scopus 로고    scopus 로고
    • The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study
    • M.E. Miller, D.E. Bonds, and H.C. Gerstein The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study BMJ 340 2010 b5444
    • (2010) BMJ , vol.340 , pp. 5444
    • Miller, M.E.1    Bonds, D.E.2    Gerstein, H.C.3
  • 29
    • 63149103614 scopus 로고    scopus 로고
    • Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association
    • J.S. Skyler, R. Bergenstal, and R.O. Bonow Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 2009 187 192
    • (2009) Diabetes Care , vol.32 , pp. 187-192
    • Skyler, J.S.1    Bergenstal, R.2    Bonow, R.O.3
  • 31
    • 71149098726 scopus 로고    scopus 로고
    • A(1c) control in primary care setting: Self-titrating an insulin analog pre-mix (INITIATEplus trial)
    • D.S. Oyer, M.D. Shepherd, and F.C. Coulter A(1c) control in primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial) Am J Med 122 2009 1043 1049
    • (2009) Am J Med , vol.122 , pp. 1043-1049
    • Oyer, D.S.1    Shepherd, M.D.2    Coulter, F.C.3
  • 32
    • 77954783077 scopus 로고    scopus 로고
    • Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: A noninferiority intensification substudy of the DURABLE trial
    • W.F. Miser, R. Arakaki, and H. Jiang Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial Clin Ther 32 2010 896 908
    • (2010) Clin Ther , vol.32 , pp. 896-908
    • Miser, W.F.1    Arakaki, R.2    Jiang, H.3
  • 33
    • 77953601896 scopus 로고    scopus 로고
    • Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: A pooled analysis of treat-to-target trials
    • V. Fonseca, J. Davidson, and P. Home Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials Curr Med Res Opin 26 2010 1621 1628
    • (2010) Curr Med Res Opin , vol.26 , pp. 1621-1628
    • Fonseca, V.1    Davidson, J.2    Home, P.3
  • 34
    • 38149073314 scopus 로고    scopus 로고
    • Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    • J. Rosenstock, A.J. Ahmann, and G. Colon Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy Diabetes Care 31 2008 20 25
    • (2008) Diabetes Care , vol.31 , pp. 20-25
    • Rosenstock, J.1    Ahmann, A.J.2    Colon, G.3
  • 35
    • 73349140858 scopus 로고    scopus 로고
    • Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study
    • A. Fritsche, M. Larbig, and D. Owens Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study Diabetes Obes Metab 12 2010 115 123
    • (2010) Diabetes Obes Metab , vol.12 , pp. 115-123
    • Fritsche, A.1    Larbig, M.2    Owens, D.3
  • 36
    • 65649091666 scopus 로고    scopus 로고
    • Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: A subgroup analysis of the IMPROVE observational study
    • J. Gumprecht, M. Benroubi, and V. Borzi Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study Int J Clin Pract 63 2009 966 972
    • (2009) Int J Clin Pract , vol.63 , pp. 966-972
    • Gumprecht, J.1    Benroubi, M.2    Borzi, V.3
  • 37
    • 12844265257 scopus 로고    scopus 로고
    • Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs
    • DOI 10.2337/diacare.28.2.260
    • P. Raskin, E. Allen, and P. Hollander Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs Diabetes Care 28 2005 260 265 (Pubitemid 40170923)
    • (2005) Diabetes Care , vol.28 , Issue.2 , pp. 260-265
    • Raskin, P.1    Allen, E.2    Hollander, P.3    Lewin, A.4    Gabbay, R.A.5    Hu, P.6    Bode, B.7    Garber, A.8
  • 38
    • 84882288796 scopus 로고    scopus 로고
    • Merck & Co., Inc. Accessed October 26, 2012
    • Merck & Co., Inc. Januvia (sitagliptin) summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/19609/ SPC/. Accessed October 26, 2012.
    • Januvia (Sitagliptin) Summary of Product Characteristics
  • 39
    • 84882265000 scopus 로고    scopus 로고
    • Amylin Pharmaceuticals, Inc. Accessed October 26, 2012
    • Amylin Pharmaceuticals, Inc. Symlin (pramlintide acetate) prescribing information. Available at: https://www.symlin.com/pdf/symlin-pi-combined.pdf. Accessed October 26, 2012.
    • Symlin (Pramlintide Acetate) Prescribing Information
  • 40
    • 77956600662 scopus 로고    scopus 로고
    • Amylin Pharmaceuticals, Inc. Accessed October 26, 2012
    • Amylin Pharmaceuticals, Inc. Byetta® (exenatide) prescribing information. Available at: http://documents.byetta.com/Byetta-PI.pdf. Accessed October 26, 2012.
    • Byetta® (Exenatide) Prescribing Information
  • 41
    • 84900559862 scopus 로고    scopus 로고
    • Amylin Pharmaceuticals, Inc. Accessed October 26, 2012
    • Amylin Pharmaceuticals, Inc. Byetta® (exenatide) summary of product characteristics. Available at: http://www.medicines.org.uk/emc/medicine/19257. Accessed October 26, 2012.
    • Byetta® (Exenatide) Summary of Product Characteristics
  • 44
    • 84882283195 scopus 로고    scopus 로고
    • Novo Nordisk A/S. Accessed October 26, 2012
    • Novo Nordisk A/S. Victoza® (liraglutide) prescribing information. Available at http://www.novo-pi.com/victoza.pdf. Accessed October 26, 2012.
    • Victoza® (Liraglutide) Prescribing Information


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.